Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan

Pegcetacoplan (Aspaveli®/Empaveli™) is a factor C3 inhibitor that is approved for the treatment of paroxysmal nocturnal hemoglobinuria. An individualized dosing strategy might be useful to improve patient-friendliness and cost-effectiveness of this very expensive drug. Therefore, the aim of this study was to develop an individualized treatment regimen for pegcetacoplan based on the pharmacokinetic-pharmacodynamic data of the manufacturer. We conducted a clinical trial simulation with the approved dosing regimen of 1080 mg twice-weekly and a target concentration intervention-based dosing regimen in patients with and without prior eculizumab use. For eculizumab-naïve patients, the target concentration intervention-based dosing regimen resulted in a comparable fraction of patients with LDH normalization (LDH < 226 U/L) and hemoglobulin normalization (> 12 g/dL) compared to the approved regimen (LDH 50.2% and 50.0% respectively and hemoglobulin 45.6% and 44.4%). A modest dose reduction of ~ 5% was possible with target concentration intervention-based dosing. An intensified dosing interval was necessary in 2.3% of the patients however an interval prolongation was possible in 28.2% of the patients. Similar results were obtained for patients prior treated with eculizumab. In this study we show the potential of an individualized dosing regimen of pegcetacoplan with can improve patient friendliness in approximately 30% of the patients and improve therapy in approximately 2% of the patients at slightly reduced costs. Supplementary Information The online version contains supplementary material available at 10.1007/s00277-024-05699-8.


Introduction
Pegcetacoplan (Aspaveli®/Empaveli™) is the first-inclass complement factor C3 inhibitor that has recently been approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) [1].PNH is a very rare and severe hematological disease characterized by complement-mediated hemolysis, thrombosis and bone marrow failure [2].
By binding to C3, pegcetacoplan inhibits the cleavage of C3 into C3a and C3b.It also binds to C3b, thereby can manifest as persistent anemia and need for blood transfusions, despite treatment with a C5 inhibitor [3].
Although pegcetacoplan administration is associated with reduced health care costs compared to C5 inhibitors eculizumab and ravulizumab [7,8], therapy is still very expensive with annual costs of US$458.000 per patient [9].The recommended dose of pegcetacoplan in adults is 1080 mg twice weekly, administered subcutaneously [1].A clear relationship between pegcetacoplan concentrations in the blood with lactate dehydrogenase (LDH) and hemoglobin response has been described [1].These data imply that an individualized dosing strategy might be useful to further individualize treatment, to improve patient-friendliness and cost-effectiveness.Therefore, the aim of this study was to develop an individualized treatment regimen for pegcetacoplan based on the pharmacokinetic-pharmacodynamic data of the manufacturer of pegcetacoplan.

Methods
We conducted a clinical trial simulation with the approved dosing regimen of 1080 mg twice-weekly and a target concentration intervention-based dosing regimen (See Table 1) in adult patients with and without prior eculizumab use.The population pharmacokinetic-pharmacodynamic model that was used for the simulations was almost completely extracted from the drug approval review documents of the Food and Drug Administration (FDA) [1].All simulations were performed with the software package NONMEM v7.5 (Icon PLC, Dublin, Ireland).
Pharmacokinetics of pegcetacoplan were described by the manufacturer with a one-compartment disposition model after absorption from the subcutaneous compartment, with first order elimination with baseline body weight as covariate on clearance and volume of distribution.Subcutaneous absorption was described with a one-transit compartment.Clearance and volume of distribution of pegcetacoplan in PNH patients were estimated to be 0.015 L/h and 3.9 L, respectively and obtained from the summary of product characteristics from the European Medicines Agency [4].
The relationship between drug concentrations and hemoglobin level was described by the manufacturer with a sigmoidal direct maximum effect model, with individual observed baseline hemoglobin level and creatinine clearance as covariates on the maximum effect (E max ).The effect of these covariates on E max was extracted from the reported data for the described effect data for the 5th, 50th and 95th percentiles of individual observed baseline hemoglobin level and creatinine clearance on Emax in the drug approval package of the FDA [1].Furthermore, the relationship between pegcetacoplan plasma concentrations and LDH levels was also described with a sigmoidal direct Emax model.The model code and a schematic representation of the model have been added to the supplemental material.We evaluated the approved dosing regimen of 1080 mg twice weekly and an individualized dosing regimen.For the individualized dosing regimen, we adjusted the dosing interval after trough level measurement on day 49 of treatment (see Table 1 for proposal), developed by testing various algorithms (data not shown).A pegcetacoplan concentration between 396 µg/ mL (EC 90 for hemoglobin response) and 597 µg/mL (EC 99 for hemoglobin response) was considered therapeutic [1].Simulations were based on the demographic data of 1171 representative adult patients, sampled from the NHANES database [3,10] with the following characteristics: weight  [1].For each scenario, we predicted hemoglobin levels, LDH levels and pegcetacoplan trough concentration during therapy and calculated the proportion of patients with hemoglobin levels < 12 g/dL (lower limit of normal for female patients), LDH levels > 226 g/dL (upper limit of normal range) and pegcetacoplan trough concentrations < 396 µg/mL (signs of inadequate therapy) at week 16 of treatment.Furthermore, we calculated the mean annual maintenance dosing costs per patient, assuming costs of US$4,404 per subcutaneous injection (yearly drug costs US$458,000 for 104 injections) [9].Lastly, for the target concentration intervention dosing regimen we calculated the proportion of patients on an intensified and prolonged dosing regimen and we compared pegcetacoplan concentrations, hemoglobin and LDH concentrations predicted for the alternative dosing strategy and the standard dose for each individual.

Results
The predicted pegcetacoplan trough concentrations, hemoglobin levels and LDH levels at week 16 of treatment for eculizumab-naïve patients for both the approved dosing regimen and the individualized dosing regimen are depicted in Fig. 1A-C.Pegcetacoplan trough concentrations were highly variable between patients for the approved dosing regimen and this variability could only be moderately reduced with the target concentration intervention.For the standard dosing regimen, 3% of the patients in the standard dosing group exhibited subtherapeutic pegcetacoplan concentrations (< 396 µg/mL) at steady state, compared to 1% of the patients in the target concentration intervention group.Median (IQR) LDH concentrations and hemoglobin levels at steady state were comparable for both the standard dosing regimen For patients with a pegcetacoplan trough concentration of > 597 µg/mL and LDH < 226 U/L after 7 weeks of treatment, standard dosing will result in median (IQR) pegcetacoplan concentrations of 720.7 (656.9-811.5)µg/ mL, hemoglobin levels of 12.0 (10.6-12.9)g/dL and LDH levels of 148.9 (119.1-176.9)U/L at week 16 of treatment.The dotted lines represents a pegcetacoplan concentration of 396 µg/ ml (EC 90 ) (A), a hemoglobin level of 12.0 g/dL (lower limit of normal range for female patients) (B) and an LDH level of 226 U/L (upper limit of normal range) (C) Fig. 2 Tukey box-and-whisker plots for pegcetacoplan trough concentrations (A), Hemoglobin levels (Hb) (B) and lactate dehydrogenase (LDH) (C) at week 16 of treatment for both standard dosing and an intensified TDM based dosing strategy for patients with a pegcetacoplan trough concentrations < 396 µg/ml after 7 weeks of treatment.
The dotted lines represents a pegcetacoplan concentration of 396 µg/ ml (EC 90 ) (A), a hemoglobin level of 12.0 g/dL (lower limit of normal range for female patients) (B) and an LDH level of 226 U/L (upper limit of normal range) (C) investigation for treatment of acute hemolytic events [12].Our proposed target concentration intervention regimen might also be of added value in optimizing therapy in these cases.
The use of a target concentration intervention regimen for pegcetacoplan requires the development of a suitable bioanalytical method to measure pegcetacoplan concentrations.A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated for the registration studies of the manufacturer [13].LC-MS/MS is a commonly used for bioanalytical analysis and associated with acceptable costs [14], especially when the analysis are being centered in for example a national laboratory.
We used a modified version of the pharmacokinetic-pharmacodynamic model of the manufacturer, that was described in the drug approval data [1,4,5].In the pharmacokineticpharmacodynamic model of the manufacturer, time-varying C3 concentration was a covariate on clearance and volume of distribution, but it was not specified how this covariate impacts these parameters.Therefore, this covariate was not added to our pharmacokinetic-pharmacodynamic model.The manufacturer stated that steady-state pegcetacoplan exposure at the 5th and 95th percentile of C3 level over time were respectively ~ 6% lower and ~ 4% higher [1].We consider this effect not clinically relevant and expect no relevant impact on our conclusions.
The pharmacokinetic and pharmacokinetic model of the manufacturer is based on data from the clinical studies with pegcetacoplan with restrictive eligibility criteria and might not entirely be illustrative for the real-world population.Therefore, our proposed dosing regimen should be prospectively evaluated in a real-world setting to confirm noninferiority with hemoglobin normalization, breakthrough hemolysis, LDH normalization, pharmacokinetic target attainment, and treatment costs.
In this study we show the potential of an individualized dosing regimen of pegcetacoplan with can improve patient friendliness in approximately 30% of the patients and improve therapy in approximately 2% of the patients at slightly reduced costs.

Declarations
Conflicts of interest NvdK has received a consultancy fee from Roche Pharmaceuticals and Novartis and is a sub-investigator in the APL2-C3G trial, Apellis.RtH has received research funding from AMGEN.The other authors declare that they have no conflict of interest.This article does not contain any studies with human participants or animals performed by any of the authors.
(124-242) U/L and the TDM based dosing regimen (LDH 174 (125-241) U/L.The fraction of patients with LDH normalization (LDH < 226 U/L) at week 16 of treatment were 70.4% in both groups.The mean yearly maintenance dose costs per patients for the standard dosing regimen and the TDM based dosing regimen were US$458,000 and US$420,626, respectively, showing a potential of ~ 8.2% reduction in yearly drug costs.An intensified dosing interval was necessary in 1.4% of the patients and interval prolongation was possible in 36.7% of the patients.For other results, see supplemental material.

Discussion
We showed a proof-of-concept for dose individualization of pegcetacoplan in PNH patients that could improve patient-friendliness in ~ 30% of the patients by interval prolongation and could improve therapy outcomes in patients with subtherapeutic pegcetacoplan concentrations (~ 2% of the patients).With an individualized dose, drug costs can be reduced by 4.7% (~ US$21.500 per patient per year) in eculizumab-naïve patients and by 8.1% (~ US$37.000) in patients with prior eculizumab use.The less frequent administration in a subpopulation may also cause a reduction in costs due to lost productivity.
In case of a target concentration dosing strategy, LDH concentrations and hemoglobin levels at steady-state were comparable with the approved dosing regimen, which suggests that pegcetacoplan exposure stayed around the plateau phase of the concentration-effect curve.
The severity of breakthrough hemolysis seems to be higher with the use of proximal complement inhibitors such as pegcetacoplan than observed with terminal complement inhibitors like eculizumab [11,12].Intensifying the dosing interval in patients with subtherapeutic concentrations might prevent breakthrough hemolysis.In the phase 3 trial directly comparing pegcetacoplan to eculizumab, two of the three patients in the pegcetacoplan group that withdrew from the study treatment had lower than average pegcetacoplan concentrations at steady-state [3].We advise that with prolonging the dosing interval, patients should be closely monitored for signs and symptoms of breakthrough hemolysis.
An intravenous formulation of pegcetacoplan and an intensified subcutaneous regimen are currently under Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http://creativecommons. org/licenses/by/4.0/.

Fig. 1
Fig. 1 Tukey box-and-whisker plots for pegcetacoplan trough concentrations (A), Hemoglobin levels (Hb) (B) and lactate dehydrogenase (LDH) (C) at week 16 of treatment for both standard dosing and TDM based dosing.The dotted lines represents a pegcetacoplan concentra-

Fig. 3
Fig.3Tukey box-and-whisker plots for pegcetacoplan trough concentrations (A), Hemoglobin (Hb) levels (B) and lactate dehydrogenase (LDH) (C) at week 16 of treatment for both standard dosing and an prolonged TDM based dosing strategy for patients with a pegcetacoplan trough concentrations > 597 µg/ml after 7 weeks of treatment.